These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 20846936

  • 1. Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia.
    Pfaller MA, Mendes RE, Sader HS, Jones RN.
    J Antimicrob Chemother; 2010 Nov; 65(11):2396-404. PubMed ID: 20846936
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS, Jones RN, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
    Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF.
    J Antimicrob Chemother; 2008 Jul; 62(1):116-21. PubMed ID: 18424792
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [Abstract] [Full Text] [Related]

  • 5. Worldwide summary of telavancin spectrum and potency against Gram-positive pathogens: 2007 to 2008 surveillance results.
    Putnam SD, Sader HS, Moet GJ, Mendes RE, Jones RN.
    Diagn Microbiol Infect Dis; 2010 Aug; 67(4):359-68. PubMed ID: 20638605
    [Abstract] [Full Text] [Related]

  • 6. The clinical positioning of telavancin in Europe.
    Masterton R, Cornaglia G, Courvalin P, Lode HM, Rello J, Torres A.
    Int J Antimicrob Agents; 2015 Mar; 45(3):213-20. PubMed ID: 25600892
    [Abstract] [Full Text] [Related]

  • 7. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
    Biedenbach DJ, Moet GJ, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Sep; 50(1):59-69. PubMed ID: 15380279
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
    Adamantia L, Antoni T.
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN, Ross JE, Bell JM, Utsuki U, Fumiaki I, Kobayashi I, Turnidge JD.
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
    King A, Phillips I, Kaniga K.
    J Antimicrob Chemother; 2004 May; 53(5):797-803. PubMed ID: 15028667
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
    Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST) Group.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
    [Abstract] [Full Text] [Related]

  • 15. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [Abstract] [Full Text] [Related]

  • 16. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance.
    Werarak P, Kiratisin P, Thamlikitkul V.
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S126-38. PubMed ID: 20364567
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.
    Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ.
    J Antimicrob Chemother; 2007 Nov; 60(5):1018-29. PubMed ID: 17855724
    [Abstract] [Full Text] [Related]

  • 18. Microbial spectrum and antibiotic susceptibility profile of gram-positive aerobic bacteria isolated from cancer patients.
    Ashour HM, el-Sharif A.
    J Clin Oncol; 2007 Dec 20; 25(36):5763-9. PubMed ID: 18089873
    [Abstract] [Full Text] [Related]

  • 19. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
    Chang MH, Kish TD, Fung HB.
    Clin Ther; 2010 Dec 20; 32(13):2160-85. PubMed ID: 21316534
    [Abstract] [Full Text] [Related]

  • 20. Activity of daptomycin against gram-positive bacterial isolates from Indian medical centres (2006-2007).
    Mathai D, Biedenbach DJ, Jones RN, Bell JM, Turnidge J, Sader HS, India Daptomycin Study Group.
    Int J Antimicrob Agents; 2009 Nov 20; 34(5):497-9. PubMed ID: 19619989
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.